Please use this identifier to cite or link to this item: https://doi.org/10.1111/j.1349-7006.2010.01736.x
Title: Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling
Authors: Matsumura, N.
Mandai, M.
Okamoto, T.
Yamaguchi, K.
Yamamura, S.
Oura, T.
Baba, T.
Hamanishi, J.
Kang, H.S.
Matsui, S.
Mori, S. 
Murphy, S.K.
Konishi, I.
Issue Date: Dec-2010
Citation: Matsumura, N., Mandai, M., Okamoto, T., Yamaguchi, K., Yamamura, S., Oura, T., Baba, T., Hamanishi, J., Kang, H.S., Matsui, S., Mori, S., Murphy, S.K., Konishi, I. (2010-12). Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Science 101 (12) : 2658-2663. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1349-7006.2010.01736.x
Abstract: The purpose of this study was to investigate a new modality of therapy against ovarian clear cell carcinoma (OCCC), a chemoresistant subtype of ovarian cancer. Microarray datasets of ovarian cancer cell lines and cancer tissues were analyzed using bioinformatic tools. The gene expression profile of OCCC was similar to that of renal cell carcinoma (RCC). This similarity was at least partially due to hepatocyte nuclear factor 1 pathway activation common to both malignancies. In addition, oncogenic pathway alterations were characteristic of OCCC including hypoxia inducible factor 1 alpha subunit and relatively high Ras activities. Therefore, we predicted that the multi-kinase inhibitor sorafenib, which is approved for RCC and suppresses Ras activity, would also be effective against OCCC. Orally administered sorafenib (40 mg/kg per day) significantly inhibited tumor growth in nude mice when it was given after inoculation with the OCCC cell line RMG-2 (P = 0.002). Furthermore, sorafenib significantly reduced tumor size when it was administered to established RMG-2 tumors (P = 0.0002), while intraperitoneal injection of cisplatin (5 mg/kg per week) did not. In conclusion, the prominent anti-tumor effect of sorafenib against OCCC indicates that sorafenib is a promising candidate drug and supports the need for clinical trials using sorafenib against OCCC. This report demonstrates a method to utilize genome-wide information to facilitate translational research for treatments against less common subtypes of cancers. (Cancer Sci 2010; 101: 2658-2663) © 2010 Japanese Cancer Association.
Source Title: Cancer Science
URI: http://scholarbank.nus.edu.sg/handle/10635/108553
ISSN: 13479032
DOI: 10.1111/j.1349-7006.2010.01736.x
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

31
checked on Jun 9, 2021

WEB OF SCIENCETM
Citations

29
checked on Jun 9, 2021

Page view(s)

92
checked on Jun 7, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.